Gapping up
In reaction to earnings/guidance:
- ONON +13.8%, CSIQ +8.2%
Other news:
- SELB +23.4% (reports Phase 3 DISSOLVE Program of SEL-212 in chronic refractory gout meets primary endpoint)
- HLIT +8.6% (partners with Charter Communications)
- GRIN +4.2% (appoints new CEO and CFO)
- NNDM +3.1% (shareholders approve Murchinson's proposals)
- BB +3% (announces new patent sale transaction with leading patent monetization company for up to $900 million)
- NTLA +3% (announces FDA regenerative medicine advanced therapy designation granted to NTLA-2002)
- BBIO +2.7% (Shares Preliminary Findings on Novel Bioassay Measuring Glycosylated Alpha-dystroglycan)
- SLRC +2.4% (notes that bank issues will not impact operations)
- CNI +2.3% (Canadian Nat'l Rail and Unifor reach tentative agreements)
- TSLA +1.9% (assigned Baa3 rating)
- SNY +1.9% (Sanofi and Regeneron Pharmaceuticals (REGN) receives EC approval for Dupixent)
- CDAY +1.8% (selected by Orica for HR and payroll)
- FUSN +1.3% (first patient in Phase 1 FPI-2059 study dosed)
- AFCG +1.2% (appoints new CFO)
Analyst comments:
- FLT +3.9% (upgraded to Outperform from Mkt Perform at Raymond James)
- HOG +3.8% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- WIX +3.3% (upgraded to Overweight from Neutral at Piper Sandler)
- META +2.8% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- EMR +1.6% (upgraded to Overweight from Equal-Weight at Morgan Stanley)